Israel’s Andromeda Biotech has been purchased by Hyperion Therapeutics for a total of $570 million. Andromeda’s DiaPep277 is a therapy for Type 1 (juvenile) diabetes. The drug is undergoing a Phase III clinical trial, with results due in the first quarter of 2015.
http://www.globes.co.il/en/article-hyperion-acquires-andromeda-for-up-to-570m-1000933645